לקסיבה

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

FOSAMPRENAVIR AS FOSAMPRENAVIR CALCIUM 700 MG

Disponible depuis:

GLAXO SMITH KLINE (ISRAEL) LTD

Code ATC:

J05AE07

forme pharmaceutique:

TABLETS

Mode d'administration:

PER OS

Fabriqué par:

GLAXO WELLCOME SA, SPAIN

Groupe thérapeutique:

FOSAMPRENAVIR

indications thérapeutiques:

Lexiva is indicated in combination with other antiretroviral agents for the treatment of Human Immunodeficiency Virus (HIV) infection in adults. The following points should be considered when initiating therapy with Lexiva/ritonavir in protease inhibitor - experienced patients: - The protease inhibitor - experienced patient study was not large enough to reach a definitive conclusion that Lexiva/ritonavir and lopinavir/ritonavir are clinically equivalent. - Once - daily administration of Lexiva plus ritonvir is not recommended for proteaseinhibitor-experienced patients.

Date de l'autorisation:

2012-01-01